- Tags: AMD
Products
FDA approves Lupin's Lucentis biosimilar injection
Ranluspec (ranibizumab-hkdz) marks the third ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.
Pipeline
Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win
Marks fourth attempt to secure approval for the potential first on-label bevacizumab product specifically formulated for IVT retinal use in the US.
Pipeline
Outlook Therapeutics wins FDA appeal for wet AMD BLA
Decision follows company’s challenge to its third rejected package of ONS-5010 / LYTENAVA (bevacizumab-vikg); fourth submission expected in June.
Research
Neuvasq highlights novel antibody approach for restoring blood-retina barrier in wet AMD and DME
Preclinical data of NVQ401 and NVQ501 demonstrate improvements in BRB integrity and function in vascular retinopathy models.
Pipeline
Lineage reports positive 36-month findings on GA cell therapy
Results from the phase 1/2a trial of OpRegen demonstrate sustained BCVA and structural improvements.
Research
PreserVision AREDS3 launch highlights B vitamins’ potential role in AMD
Bausch + Lomb advanced PreserVision formula spotlights the unique B-vitamin complex in reducing the risk for AMD, especially in earlier stages.
Events
Nutritional supplementation is redefining eye health management
Highlights from Bausch + Lomb’s first-ever consumer summit.
Pipeline
Merck kicks off phase 2b/3 trial on tri-specific antibody for wet AMD
Merck initiates next phase of clinical testing in ophthalmology with two candidates targeting nAMD and DME.
Events
Retina Summit 2026: OD updates for AMD management and imaging
Key takeaways from AAO’s one-day meeting explore retina care’s shift from referral-based to decision-making at the OD level.
Pipeline
Ocular Therapeutix releases additional phase 3 AXPAXLI data for wet AMD
Data from SOL-1 phase 3 data will become the basis of a planned NDA submission in near future.
Research
Does smoking age your eyes?
Mouse model study finds cigarette smoke may cause changes in eye cells similar to aging damage, with younger and older cells differing in protection.Pipeline
FDA accepts Outlook Therapeutics' request over rejected wet AMD BLA
Company challenges decision on failed third submission package of ONS-5010 / LYTENAVA (bevacizumab-vikg), with a decision expected in May.
Pipeline
i-Lumen Scientific earns FDA IDE clearance for dry AMD trial
Biotech company is expanding the global i-SIGHT 2 pivotal trial evaluating its non-invasive bioelectric stimulation therapy as an in-office treatment.
Products
FDA approves expanded EYLEA HD dosing intervals
VEGF inhibitor cleared for every 20 weeks among wet AMD and DME patients; clearance based on 96-week data from the PHOTON and PULSAR pivotal trials.
Products
Eyedaptic launches latest version of AI-based smart glasses for AMD
Designed for patients with retinal diseases, the EYE7 is an integrated wearable solution with real-time vision enhancements and a new visual assistant.
Research
Study urges alternative tracking for wet AMD poor responders
Structural change tracking indicates subretinal fibrosis may drive vision loss, calling for a shift in patient monitoring.
Pipeline
EyePoint begins dosing in phase 3 DME trials for DURAVYU
COMO and CAPRI pivotal studies are evaluating vorolanib insert when intravitreally-injected every 6 months; topline data expected H2 2027.
Pipeline
Ocular Therapeutix reports positive phase 3 SOL-1 superiority data for wet AMD
AXPAXLI is the first and only novel drug to demonstrate superiority to an approved anti-VEGF treatment in an FDA-aligned wet AMD study.
Pipeline
4DMT completes enrollment for phase 3 wet AMD gene therapy trial
4FRONT-1 study is evaluating 4D-150 as a single, low-dose IVT injection among treatment-naïve wet AMD patients; topline data expected in H1 2027.
Research